COMPASS Pathways’ (CMPS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $45.00 price target on the stock.

Several other research analysts have also weighed in on the stock. Stifel Nicolaus began coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective on the stock. Canaccord Genuity Group dropped their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $21.83.

COMPASS Pathways Trading Down 0.5 %

NASDAQ CMPS opened at $4.02 on Tuesday. COMPASS Pathways has a 52 week low of $3.17 and a 52 week high of $11.72. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The stock’s 50 day moving average price is $4.05 and its two-hundred day moving average price is $5.17. The stock has a market capitalization of $275.05 million, a price-to-earnings ratio of -1.83 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in COMPASS Pathways in the 4th quarter worth about $41,000. Wealthfront Advisers LLC bought a new stake in COMPASS Pathways during the fourth quarter worth about $43,000. Flagship Harbor Advisors LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $43,000. Conservest Capital Advisors Inc. increased its stake in shares of COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in COMPASS Pathways during the fourth quarter worth about $54,000. Institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.